At last month's JPMorgan Healthcare ... Revenues from the Sanofi collaboration were $1.2 billion, of which $1 billion related to our share of collaboration profits. Regeneron's share of profits ...

It was another strong quarter for Dupixent – a drug for inflammatory diseases that it develops with Sanofi ... Baron Health Care Fund stated the following regarding Regeneron Pharmaceuticals ...

The oncology sector covers the entire cancer care process ... an eczema treatment whose rights Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares with Sanofi. Eylea, which Regeneron ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi ... note that Regeneron co-developed Eylea with the HealthCare unit of Bayer ...